Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: extended follow-up of a phase I/II study
No human RCT has established a minimum effective dose, maximum tolerated dose, or therapeutic window
We analyzed age, sex, comorbidities, biochemical data, MELD score, Child-Pugh, presence of recurrence (based on AASLD guidelines), graft rejection and use of immunosuppressant
It reduces oxidative stress, which is essential for shielding nerve cells from harm caused by neurological conditions (6)
Human or veterinary use is prohibited under regulations
US$ 28.81
US$ 24.61
US$ 25.59
US$ 21.09
US$ 22.20
